Hillary Clinton, the Democratic front runner in the race for the White House, pledged this week to crack down on the growing cost of prescription drugs and out of pocket medical expenses in the United States after Turing Pharmaceuticals announced that it was hiking the price of the drug Daraprim from $13.50 to $750 a pill. Aimee Keane asks David Crow about the sharp falls in biotech stocks that followed and whether plans such as Mrs Clinton's will end price-gouging. Music: "Starday" by Podington Bear.

iTunes Stitcher audioBoom SoundCloud Overcast RSS


Copyright The Financial Times Limited 2017. All rights reserved.
myFT

Follow the topics related to this show

Comments have not been enabled for this podcast.